|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, February 13, 2019 ) The Business Research Company’s respiratory diseases drugs global market report, covers the year-on-year growth of the global respiratory diseases drugs market historic and forecast growth. It also includes chapters on the respiratory diseases drugs market trends, geographical analysis, and competitive landscape.
Order The Report At: https://www.thebusinessresearchcompany.com/report/respiratory-diseases-drugs-global-market-report
The global respiratory diseases drugs market size is expected to reach $70 billion by 2022, significantly growing at a CAGR of around 6.5% during the forecast period.
Respiratory Diseases Drugs Market Trends
The respiratory diseases drugs market consists of sales of respiratory diseases drugs and related services by entities (organizations, sole traders and partnerships) that produce drugs to treat respiratory diseases such as asthma, acute bronchitis, emphysema, cystic fibrosis and other diseases. This industry includes establishments that produce anti-asthmatics and COPD drugs to prevent acute attacks caused by respiratory diseases and cough and cold preparations to treat cough and cold.
The demand for PSE-containing cold, allergy, and sinus products is growing due to their effectiveness and convenience. PSE is an active ingredient found in various cold, allergy, and sinus drugs that can provide congestion relief. However, PSE-containing medicines are mostly sold as a prescription drug, as PSE can also be used for the illegal manufacture of methamphetamine, a recreational drug. This has led drug manufacturers to produce tamper-resistant PSE products. For instance, in March 2017, pharmaceutical companies Acura Pharmaceuticals Inc. and MainPointe Pharmaceuticals LLC entered into an agreement, enabling MainPointe Pharmaceuticals LLC to market NEXAFED and NEXAFED Sinus products in the US and Canada. These drugs utilize tamper-resistant PSE formulation to prevent the illicit production of methamphetamine.
The growth in the Respiratory Diseases Drugs market is due to rise in global air pollution levels will lead to higher number of respiratory diseases thus driving the respiratory drugs market.
Download A Sample Of The Report: https://www.thebusinessresearchcompany.com/sample.aspx?id=2143&type=smp
The global respiratory diseases drugs market report covers the following regions under the geographical analysis section: Asia Pacific, Western Europe, North America, Middle East, Africa, South America, and Eastern Europe. Major countries under each of these regions are also covered under the country analysis chapters.
With the increase in demand for drugs for respiratory diseases as a result of rise air pollution levels around the world, the global respiratory diseases drugs market is expected to increase in potential and scope. TBRC’s report also covers the respiratory diseases drugs drivers and restraints in the market.
The global respiratory diseases drugs market’s segment shares in each geographic region are mentioned in the report, along with the historic and forecast growth rates for each segment presented visually with supporting reasons to justify the growth rates.
The top companies included in the global respiratory diseases drugs market report are GlaRespiratory Diseases DrugsoSmithKline Plc, AstraZeneca Plc, Merck & Co, Novartis AG, and Johnson & Johnson.
About The Business Research Company:
The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.
Contact Information
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
The Business Research Company
Marketing TBRC
+91 8897263534
Marketing@tbrc.info
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
